MPP3

Across TCGA pan-cancer cohorts, MPP3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MPP3 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MPP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MPP3 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

LUAD, LIHC, and BLCA are the cancer types where MPP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.136	0.814	<.001	40	view →
LIHC	DFS	Median	All	0.043	0.527	<.001	12	view →
BLCA	OS	Median	IV	0.141	0.589	.018	6	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →
SKCM	DFS	Median	II,III,IV	1.000	0.547	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MPP3–LUAD (OS)

Open the LUAD breakdown →